FBRX - Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market
- The company’s key product candidate is FB-401, a topical live biotherapeutic, with three therapeutic strains of commensal gram-negative bacteria Roseomonas mucosa.
- FB-401 is being developed in mild to moderate atopic dermatitis and has FDA Fast track designation based on Phase 1a/2 data.
- I'm bullish on the upcoming Phase 2 data for FB-401 in atopic dermatitis in the middle of this year.
- FB-401 could reach a peak of $2B in sales. The stock is undervalued at its current market cap of $505M (enterprise value of $392M).
- The stock is up approximately 20% in less than two weeks since this idea was first published in the Marketplace premium service. I expect more upside ahead.
For further details see:
Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market